Topics

STAT Plus: How Amgen plans to BiTE into CAR-T’s hype

04:45 EDT 16 Aug 2019 | STAT

Amgen's Greg Friberg, who heads up the company's oncology global development, spoke with STAT about the science behind BiTES, the hope for future therapies, and the potential safety concerns.

Original Article: STAT Plus: How Amgen plans to BiTE into CAR-T’s hype

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: How Amgen plans to BiTE into CAR-T’s hype"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...